Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature
- 1 January 2008
- journal article
- case report
- Published by SAGE Publications in Lupus
- Vol. 17 (1), 50-55
- https://doi.org/10.1177/0961203307085251
Abstract
Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by a hypercoagulable state related to persistently elevated levels of antiphospholipid antibodies (aPL). Current treatment for APS is only partially effective and new therapies are strongly needed. We report on a case of a 50 years old man with APS who suffered from recurrent thromboembolic episodes despite conventional anticoagulant treatment. Eight years after the first thrombotic manifestation he was diagnosed with a large B cell non-Hodgkin lymphoma. Treatment with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) plus rituximab was started with partial clinical remission of lymphoma and normalization of aPL levels with a three years follow-up period free of thrombotic episodes. A review of the literature revealed that only 12 case reports on the use of rituximab in patients with primary, secondary and catastrophic APS have been published. Current knowledge clearly suggests the need for clinical trials to evaluate the effect of rituximab in the treatment of resistant APS. Lupus (2008) 17, 50—55.Keywords
This publication has 14 references indexed in Scilit:
- Limited effect of rituximab on thrombocytopaenia and anticardiolipin antibodies in a patient with primary antiphospholipid syndromeAnnals of Hematology, 2006
- Management of Antiphospholipid Antibody SyndromeJAMA, 2006
- Successful treatment of thrombocytopenia in primary antiphospholipid antibody syndrome with the anti-CD20 antibody rituximab—monitoring of antiphospholipid and anti-GP antibodies: a case reportAnnals of Hematology, 2005
- Rituximab chimeric anti‐CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpuraAmerican Journal of Hematology, 2005
- Long-term remission from life-threatening hypercoagulable state associated with lupus anticoagulant (LA) following rituximab therapyAmerican Journal of Hematology, 2005
- The efficacy and safety of B‐cell depletion with anti‐CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpuraBritish Journal of Haematology, 2004
- B cell depletion may lead to normalization of anti-platelet,anti-erythrocyte and antiphospholipid antibodies in systemic lupus erythematosusThrombosis and Haemostasis, 2004
- Humoral immunity and long-lived plasma cellsCurrent Opinion in Immunology, 2002
- International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an International workshopArthritis & Rheumatism, 1999
- The antiphospholipid syndrome: ten years onThe Lancet, 1993